
Opinion|Videos|February 22, 2024
Immunotherapy-Based Regimen Efficacy/Safety Updates
Author(s)Hans Hammers, MD, PhD
Dr. Hammers discusses recent efficacy and safety data updates from CHECKMATE-214, KEYNOTE-426, and CHECKMATE-9ER trials.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
First Patients Dosed With TLX597-Tx in Trial for mHSPC
4
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
5































